Regeneron Pharmaceuticals (REGN) Cash from Investing Activities (2009 - 2026)

Regeneron Pharmaceuticals has reported Cash from Investing Activities for 18 years, with the latest figure at -$428.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 166.24% year-over-year to -$428.9 million; the trailing twelve-month figure through Mar 2026 stood at -$1.7 billion (down 1177.53% YoY), and the FY2025 full-year result was -$629.1 million, up 74.51% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$428.9 million, down from $220.3 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $647.5 million in Q1 2025, with the low at -$2.4 billion in Q2 2023.
• Average Cash from Investing Activities over 5 years is -$617.4 million, with a median of -$428.9 million recorded in 2026.
• Peak annual rise in Cash from Investing Activities reached 629.61% in 2024, while the deepest fall reached 615.78% in 2024.
• Tracing REGN's Cash from Investing Activities over 5 years: stood at -$1.9 billion in 2022, then soared by 96.44% to -$66.2 million in 2023, then surged by 629.61% to $350.6 million in 2024, then tumbled by 37.16% to $220.3 million in 2025, then slumped by 294.69% to -$428.9 million in 2026.
• The last three Cash from Investing Activities figures came in at -$428.9 million (Q1 2026), $220.3 million (Q4 2025), and -$402.9 million (Q3 2025), per Business Quant data.

Peer Comparison